Ke hoʻolālā nei i ka GLP‑1 Peptide Hoʻololi a me ka Scale-Up Workflows no nā polokalamu unuhi.

Pane wikiwiki

Proficient in GLP‑1 peptide structural modification and lipidation chemical transformation, scalable manufacturing via SPPS‑LPPS combined synthesis technology, product certification analysis relying on HPLC and MS for Certificate of Authentication validation, alongside the development and process optimization of GMP-compliant 3D printed sustained-release delivery systems for peptide pharmaceuticals.

Ke hoʻolālā nei i ka GLP‑1 Peptide Hoʻololi a me ka Scale-Up Workflows no nā polokalamu unuhi.

Ke hoʻolālā ʻana i ka GLP-1 Peptide Hoʻololi a me ka Scale-Up Workflows no nā polokalamu unuhi

Manaʻo Manaʻo: ʻO ka hoʻokūkū unuhi ma Incretin Engineering

Glucagon-like peptide-1 (GLP-1) nā agonists loaʻa a me nā mea ʻelua / triple incretin co-agonists (GLP-1/GIP/Glucagon) ʻO kekahi o nā papa therapeutic transformative loa i ka maʻi metabolic, obesity, a me nā maʻi neurodegenerative. Eia naʻe, ʻo ka unuhi ʻana i kahi kaʻina GLP-1 ʻano ʻāhiu i loko o kahi moho lāʻau lapaʻau hiki ke kūʻai ʻia e hōʻike ana i nā bottlenecks kemika a me ka biophysical.. ʻŌiwi GLP-1 (7-36) hōʻike ka amide i kahi ola plasma hapalua ola ($t_{1/2}$) o ka emi mai 2 mau minuke ma muli o ka proteolysis wikiwiki e Dipeptidyl Peptidase-4 (DPP-IV) at the $\text{Ala}^8-\text{ʻO Glu}^9$ paʻa peptide, hui pū me ka hoʻomaʻemaʻe renal ($NMWCO \approx 30-50\text{ kDa}$).

No ka hoʻokō ʻana i hoʻokahi pule i hoʻokahi pule a i ʻole hoʻokahi mahina, Pono nā polokalamu unuhi e hoʻohui i nā hoʻololi kemika paʻakikī—me nā ʻakika amino kūlohelohe ʻole., ʻaoʻao-chain fatty acid acylation (lipidation), Poly kikoʻī pūnaewele(ethylene glycol) (PEGylation), a me nā lima hōʻailona diagnostics. Akā naʻe, nā koho mua i hana ʻia i ka wā ʻike-pae solid-phase peptide synthesis (SPSS) hana pinepine i nā ʻano hemahema koʻikoʻi i ka wā hoʻonui:

  • Huihui & Gelation: Hydrophobic fatty acid side chains or polydisperse PEG polymers drive intermolecular $\beta$-sheet self-assembly during cleavage and purification.
  • Nā mea haumia Diastereomeric: ʻO ka hui pū ʻana o nā ʻāpana lipophilic paʻakikī e hoʻonui i ka racemization ma nā kikowaena chiral..
  • Hoʻopaʻa huna: ʻO ka hui pū ʻana o nā peptides holoi pili pili ($n-1, n-2$) a me nā ʻano hoʻohaʻahaʻa ʻaoʻao ʻaoʻao isobaric ($D\text{-ʻO Asp}$, $\beta\text{-ʻO Asp}$) i ka wā Reverse-Phase High-Performance Liquid Chromatography (RP-HPLC).
  • Kaʻina ʻAʻole Linearity: ʻO ka hoʻonui ʻana mai ka nui o ka noiʻi milligram a hiki i ka hana hoʻokele multigram a me ka kilokani e alakaʻi i ka hoʻouka nui ʻana o ka chromatographic non-linear a me ka hāʻule ʻana o ka wela..

Hōʻike kēia anga i kahi ʻano hana ʻenekinia hope-a-hope e hoʻopili pololei ana i nā koho hoʻololi kaʻina hana mua i ka hoʻonui i lalo., hōʻoia analytical, nā koho hana hou e like me ka paʻi 3D mākaukau GMP, a me ka hoʻokō hoʻoponopono ICH.


Ke kahua 1 - Hoʻololi ʻana i ke kaʻina hana mua & Nā Kemika Hoʻonui Half-Life

ʻO ka hoʻolālā ʻana i kahi unuhi unuhi GLP-1 e pono ai i kahi hoʻolālā hoʻololi kemika i hoʻopaʻa ʻia i ka manawa like., hoʻomaʻemaʻe renal lohi, a mālama i nā kinetics hoʻopaʻa ʻia ($EC_{50}$).

[Native GLP-1 (7-36)] : H2N-His7-Ala8-Glu9-Gly10-Thr11-Phe12-Thr13-Ser14-Asp15-Val16...-Lys26...-Lys34-Gly37-OH
                                   |
                         (DPP-IV Cleavage Point)

[Engineered Analog]   : H2N-His7-[Aib8]-Glu9-Gly10-Thr11-Phe12-Thr13-Ser14-Asp15-Val16...-[Lys26(Spacer-FattyAcid)]...-[Arg34]-Gly37-NH2
                                   |                                                          |
                         (Protease Resistant)                                        (Albumin Binding Handle)

1. Hoʻopaʻa Enzymatic: Kū'ē DPP-IV

Substituting the native $\text{Ala}^8$ residue with $\alpha$-aminoisobutyric acid ($\kikokikona{Aib}^8$) or $D\text{-Ala}^8$ ke hoʻolauna nei i ka hoʻopaʻapaʻa steric a puni ka $N$-terminal catalytic cleavage kahua me ka hoʻopau ʻole ʻana i ka alpha-helical docking i loko o ka GLP-1 receptor extracellular domain..

ʻO ka helu hoʻohaʻahaʻa mau ($k_{popoki}/K_m$) no ka DPP-IV enzymatic cleavage ua ho'ēmiʻia e like me ka papa mua Michaelis-Menten kinetics:

$$v = \frac{V_{max} [S]}{K_m \left(1 + \frac{[I]}{K_i}\akau) + [S]}$$

Where substitution with $\text{Aib}Hoʻonui ka ^8$ i ka pale ikehu hoʻāla kūloko ($\Delta G^\ddagger$), ka hoʻolilo ʻana i ka cleavage rate he mea ʻole ($k_{obs} < 10^{-6}\kikokikona{ s}^{-1}$).

2. Kemika Lipidation: C16 vs. C18 Diacid Architecture

ʻO ka hui pū ʻana o nā kaulahao momona momona e hoʻolalelale i ka hoʻopaʻa ʻana i ka Human Serum Albumin (HSA, $K_d \sim 10-50\text{ }\mu\text{M}$), e hōʻemi ana i ka kānana renal a me ka pale ʻana i ka iwi kuamoʻo peptide mai nā endopeptidases non-specific..

Wahi a ka noiʻi i paʻi ʻia ma E noʻonoʻo hou i nā Peptides ma Lipidation Half-Life Extension Kinetics, ka hoʻololi ʻana mai kahi C16 palmitoyl mono-acid (Liraglutide hale hana, $t_{1/2} \sim 13\text{ h}$) to a C18 octadecanedioic acid diacid via a flexible $\gamma\text{-Glu-OEG}_2$ spacer ($\gamma\text{-L-glutamyl-(\beta-alanyl-2,2′-(ethylenedioxy)bis(ethylamine))}$, ʻO ka hoʻolālā Semaglutide) extends human plasma half-life to $\sim 165\text{ hola}$.

  Lys26 Side Chain ($\epsilon$-amine)
         |
    (NH-CO-CH2)
         |
    [$\gamma$-Glu Spacer]
         |
    [OEG Linker 1: 8-amino-3,6-dioxaoctanoic acid]
         |
    [OEG Linker 2: 8-amino-3,6-dioxaoctanoic acid]
         |
    [Octadecanedioic Acid: HOOC-(CH2)16-CO-]

3. Paena-Specific PEGylation Chemistries

No ka hōʻiliʻili ʻana o ka ʻōnaehana non-covalent a lōʻihi paha, monodisperse a i ʻole polydisperse Poly(ethylene glycol) (PEG, 20–40 kDa) hoʻohui ʻia me nā lima bio-orthogonal kikoʻī kikoʻī:

  • Thiol-Maleimide Ligation: Reaction of an engineered $Cys$ residue with Maleimide-PEG at $\text{pH } 6.5 – 7.2$.
  • Oxime Ligation: Reaction of an aminooxy-functionalized PEG with an $N$-terminal aldehyde or keto-amino acid at $\text{pH } 4.5 – 5.5$.

E like me ka palapala ma ACS Bioconjugate Chemistry Studies ma PEGylation Kūikawā Kūikawā, Hoʻonui nui ka PEGylation i ka radius hydrodynamic ($R_h$), helu ʻia ma o ke Kānāwai Scaling Polymer:

$$R_h = K_{PEG} \cdot (M_w)^a$$

Where $M_w$ is the PEG molecular weight and $a \approx 0.55-0.60$ i loko o nā pā wai. ʻOiai ʻo PEGylation e pale pono i ka kānana glomerular, hiki iā ia ke attenuate i ka ikehu hoʻāla ʻana ma muli o ka pale steric, e koi ana i ka lōʻihi o ka loulou.

4. Hoʻomaʻamaʻa & Nā Lima Lepili Analytical

Pono nā haʻawina unuhi mua i ka ADME quantitative, māhele ʻiʻo, a me ka hoʻopaʻa ʻana i ke kelepona. Pono e hoʻolālā ʻia ka hoʻohui ʻana i nā pūʻulu nūhou i mea e pale aku ai i ka pili ʻana o GLP-1R.:

  • Nā huaʻōlelo Fluorescent: FITC a i ʻole Cyanine5.5 (Cy5.5) hoʻohui ʻia ma o ka Lysine acylation koho a i ʻole Thiol-alkylation.
  • Nā Lepili Isotopic: Kaulike $^{13}\kikokikona{C}/^{15}\kikokikona{N}$ nā ʻakika amino i hoʻopaʻa ʻia i ka isotope i hoʻohui ʻia i loko o ke kaʻina hydrophobic kumu no ka helu LC-MS/MS paʻa. (Nā ʻano MRM/PRM) i nā matrix plasma preclinical.

Papahana ASCII 1: Palekana Orthogonal & Hoʻohui ʻaoʻao-Chain

To achieve site-specific acylation at $\text{Lys}^{26}$ while leaving $\text{Lys}^{34}$ (or $\alpha\text{-NH}_2$) hana ole, he mea pono ka hoʻolālā pale orthogonal:

  Fmoc-Lys(Mtt)-OH or Fmoc-Lys(Alloc)-OH at Position 26
                          |
    [Assembly of Core Peptide Chain on Resin via SPPS]
                          |
  Selective De-protection of Mtt (1% TFA/DCM) or Alloc (Pd(PPh3)4/PhSiH3)
                          |
  Solid-Phase Coupling: Fmoc-OEG-OH -> Fmoc-OEG-OH -> Fmoc-Glu-OtBu -> Mono-tert-butyl octadecanedioate
                          |
  Global Deprotection & Resin Cleavage (TFA / TIS / H2O / EDT = 92.5 : 2.5 : 2.5 : 2.5)

No nā hui e loiloi ana i nā kaʻina hoʻololi paʻakikī, leveraging i hoʻokumu ʻia kahua hana peptide synthesis maʻamau me nā mana hoʻolaʻa hoʻomalu orthogonal e hōʻoiaʻiʻo i ka maʻemaʻe maʻemaʻe mua ma mua o ka hoʻonui ʻana i lalo.


Ke kahua 2 — Hoʻoholo-Phase Bioconjugation & ʻEnekinia Hana Hana

Hoʻoholo hoʻoholo pilikia: ʻO ka lāhui & ʻO ka mana o ka Acylation

I ka hoʻonui ʻana i ka bioconjugation o nā loulou lipophilic (e.g., C18 diacids with $\gamma\text{-Glu-OEG}_2$ mau mea wehe), ʻO nā ʻāpana hopena maikaʻi ʻole e hoʻoulu i nā profile haumia kikoʻī:

                  BIOCONJUGATION TROUBLESHOOTING FLOWCHART
                                     |
    +--------------------------------+--------------------------------+
    |                                                                 |
    v                                                                 v
[Symptom: Over-Acylation Impurity]               [Symptom: Racemization at Chiral Linker]
(Nα,Nε-bis-acylated product > 1.5%)             (D-Glu / D-Lys diastereomer species > 0.5%)
    |                                                                 |
    +---> Root Cause: pH > 8.8 (N-terminal            +---> Root Cause: Excess base / High Temp
    |     α-amine becomes unprotonated)            |     during activated ester coupling
    |                                              |
    +---> Action: Implement automated              +---> Action: Switch from HATU to Oxyma Pure/DIC;
          pH-stat titration at pH 8.2-8.5                 maintain reaction temperature at 18°C–20°C
ʻAno hāʻule / haumia Kumu Kumu Hōʻailona Analytical Kaʻina hana hoʻoemi
$N^\alpha,N^\epsilon$-Bis-Acylation Reaction $\text{pH} > 8.8$ a i ʻole ka lāʻau acylating stoic. ($>1.5\kikokikona{ equiv.}$) UHPLC peak co-eluting post-main peak ($+M_{lipid}$ MW hoʻololi ma MS) Tighten $\text{pH}$ hoʻomalu i $8.2-8.5$; palena stoi. to $1.05-1.15\text{ equiv.}$; e hoʻohana i ka pH-stat automated titration
Diastereomeric Racemization ($D\text{-ʻO Glu}$) Hoʻonui i nā manawa pane me ke kumu ikaika (e.g., DIPEA) ma $>25^\circ\text{C}$ Chiral LC-MS or Marfey’s method showing $D\text{-ʻakika amino} > 0.2%$ Hoʻololi i ka DIPEA me $N$-methylmorpholine; lower coupling temp to $18-20^\circ\text{C}$; hoʻohana i ka Oxyma Pure / DIC
Lipid Ester Hydrolysis / Māhele Kiʻekiʻe loa ka lakio hoʻopaʻa wai ($>40%\kikokikona{ H}_2\text{O}$) ke kumu o ka ester hydrolysis MS peak pili ana i ka hydrolyzed diacid precursor Optimize solvent ratio to $\text{DMF/Wai } 80:20\kikokikona{ v/v}$ or $\text{NMP/DMSO}$; kaohi i ka hana wai

ʻOiai hiki ke hoʻololi ʻia nā hoʻololi liʻiliʻi ma luna o ka resin, ʻO ka hana nui nui e kuhikuhi pinepine i kahi ala hybrid: synthesizing i ka iwi kuamoʻo linear peptide ma ka resin, a ukali ʻia e ka hoʻohui ʻana i ka hopena hope-cleavage-phase conjugation o nā mea hoʻopili lipid pipiʻi a i ʻole nā ​​polymers PEG e hōʻemi i ka ʻōpala waiwai..

+-----------------------------------------------------------------------------------+
|                        SOLUTION-PHASE BIOCONJUGATION PARAMETERS                   |
+--------------------------+--------------------------------------------------------+
| Parameter                | Optimal Process Window                                 |
+--------------------------+--------------------------------------------------------+
| Peptide Concentration    | 5.0 - 15.0 mM                                          |
| Acylating Agent Stoich.  | 1.05 - 1.25 equiv. relative to target Lys             |
| Solvent System           | DMF / Water (70:30 v/v) or NMP / DMSO mixtures         |
| Reaction pH              | 8.2 - 8.5 (controlled via N-methylmorpholine or TEA)   |
| Reaction Temperature     | 18°C - 22°C                                            |
| Coupling Reagents        | PyBOP / Oxyma Pure or HATU / HOAt                      |
+--------------------------+--------------------------------------------------------+

Chemoselectivity & $pK_a$ Manao

Selective acylation of the $\epsilon\text{-amino}$ group of $\text{Lys}^{26}$ ($pK_a \approx 10.5$) over the $N$-terminal $\alpha\text{-amino}$ hui ($pK_a \approx 8.0$) pono e mālama pono i ka pH buffer. Operating within a narrow window of $\text{pH } 8.2 – 8.5$ maintains the $\alpha\text{-amine}$ i loko o kahi kūlana protonated ($\kikokikona{-NH}_3^+$), while allowing sufficient unprotonated nucleophilic $\epsilon\text{-amine}$ ($\kikokikona{-NH}_2$) e hana me ka NHS-esters ikaika a i ʻole tetrafluorophenyl (TFP) esters.

ʻO ka lua o ka hoʻololi ʻana o ka hopena mau ($k_{obs}$) no ka bioconjugation koho i hoomaluia e:

$$\frac{d[\kikokikona{Hoʻohui}]}{dt} = k_0 \cdot \left(\frac{1}{1 + 10^{(pK_a – \text{pH})}}\akau) [\kikokikona{Peptide}] [\kikokikona{Agena Acylating}]$$

Ke holo nei i nā hopena bioconjugation i loko o a bioconjugation kūikawā a me ka suite hoʻololi ua lako me ka automated pH-stat feedback loops e hoopau i ka over-acylation side products ($N\alpha,N\epsilon\text{-bis-acylated}$ ʻano ʻano).


Ke kahua 3 — Nā Hana ʻĀpana Hoʻonui: SPPS i SPPS-LPPS Hybrid Synthesis

Ke hoʻonui nei i ka hana ʻana o GLP-1 mai ka nui o nā pae hoʻokolohua (0.1–1.0 g) i kilo kilo pailaka pūʻulu hoʻolauna thermodynamic a me physical 'enekinia palena.

       [LAB SCALE: Pure SPPS]                    [PILOT/COMMERCIAL SCALE: Hybrid SPPS-LPPS]
  0.1 - 100 g Batch Capacity                       1.0 kg - 100 kg Batch Capacity
  - High DMF/NMP consumption (>1000 L/kg)           - Slashes solvent consumption by 60%
  - Crude purity drops on long sequences            - Fragment purity >95% prior to condensation
  - Resin swelling & pressure drop limits           - Controlled solution-phase thermodynamics

1. Paʻa-Phase vs. ʻO ka hoʻoheheʻe ʻana i ka ʻāpana wai

Linear SPPS o 30-40 mer GLP-1 analogs e ʻike i ka hōʻiliʻili exponential o nā haumia ʻoki. ($n-1, n-2$) ma muli o ka hōʻiliʻili steric ma ka moena resin. E like me ka kikoʻī ma ka ʻIke ʻia ʻo Bachem Knowledge Center ma ka Industrial SPPS Scale-Up, hāʻule ka huina o ka hua ʻai ma lalo $20%$ ma ka pālākiō inā hana ʻia ma ka laina laina.

No ka lanakila ʻana i kēia, apono nā polokalamu unuhi hou SPPS-LPPS Hybrid Fragment Condensation, e like me ka mea i hoikeia e ka PDA Leta ma Hybrid SPPS-LPPS Fragment Condensation.

ʻO nā ʻāpana peptide pale pōkole (e.g., Māhele A: koena 7–14; Māhele B: koena 15–26; Māhele C: koena 27–37) ua synthesized kaawale ma 2-chlorotriyl chloride resin, hoʻokaʻawale ʻia ma lalo o nā kūlana ʻakika mālie ($0.5-1.0%\kikokikona{ TFA}$ ma DCM) e mālama i nā hui pale kaulahao ʻaoʻao, a hoʻohui ʻia i loko o ka pae hoʻonā:

 Fragment A (7-14)-OH + H-Fragment B (15-26)-OtBu 
                          |  (Coupling: DIC / Oxyma Pure, DMF/DCM, 20°C)
                          v
           Protected Intermediate AB (7-26)-OtBu
                          |  (Deprotection)
                          v
      H-Intermediate AB (7-26)-OH + H-Fragment C (27-37)-NH2
                          |  (Coupling: PyBOP / HOAt)
                          v
            Full-Length Protected GLP-1 Analog
                          |  (Global Deprotection: TFA Cocktail)
                          v
                   Crude GLP-1 Conjugate

ʻO ka hōʻailona hōʻailona hoʻonui: Ma nā ho'āʻo hoʻolālā hoʻokele (1.0–5.0 kg holo pūʻulu), ka hoʻohana ʻana i kēia ʻāpana 3 SPPS-LPPS condensation protocol e hoʻokō mau i ka hopena-phase fragment coupling i nā hua $> 85%$ me nā ʻāpana ʻāpana i mālama ʻia $> 92%$ ma mua o ka condensation hope. Eia kekahi, elevating RP-HPLC column temperatures to $50^\circ\text{C} – 55^\circ\text{C}$ i ka wā C4 hoʻomaʻemaʻe hoʻomaʻemaʻe hoʻonā lipophilic back-pressure hysteresis, hoʻomaikaʻi i nā hua hoʻōla e $18-22%$ hoʻohālikelike ʻia me nā holo wela ambient.

2. Hoʻonui Chromatographic & Column-Linearity

ʻO ka hoʻomaʻemaʻe ʻana o ka lipidated a i ʻole PEGylated GLP-1 peptides e hilinaʻi ʻia ma Reverse-Phase HPLC (RP-HPLC) me ka hoʻohana ʻana i ka C4 a i ʻole C18 silica stationary phases ($100-300\kikokikona{ \AA}$ nui pore, $10\kikokikona{ }\mu\text{m}$ nui ʻāpana).

I ka wā hoʻonui, kiʻekiʻe o ka moena kolamu ($L$) a me ka laina laina ($u$) pono e paʻa mau i ka wā e hoʻonui ana i ke anawaena kolamu ($D$) e mālama i ka hoʻonā chromatographic ($R_s$):

$$\frac{V_1}{V_2} = \left(\frac{D_1}{D_2}\akau)^2$$

$$R_s = \frac{\sqrt{N}}{4} \hema(\frac{\alpha – 1}{\alpha}\akau) \hema(\frac{k'}{1 + k'}\akau)$$

                                  CHROMATOGRAPHIC RESOLUTION DYNAMICS
  Analytical (4.6 mm ID)        Preparative (50 mm ID)           Industrial (300-600 mm ID)
  [Peak A][Peak B]   -->        [ Peak A ][ Peak B ]   -->       [  Peak A  ][  Peak B  ]
  (Sharp separation)            (Slight peak broadening)         (Mass loading non-linearity)

Hoʻonui nā kaulahao lipid hydrophobic i nā manawa paʻa ($k’$), e koi ana i nā wela hana o ke kolamu kiʻekiʻe ($45^\circ\text{C} – 60^\circ\text{C}$) a me nā gradients hoʻololi organik (Isopropanol/Acetonitrile in $0.1%\text{ TFA}$ or $20\text{ mM } \kikokikona{NH}_4\text{OAc}$) e pale i ka fouling kolamu a me ka hysteresis.


Ke kahua 4 — Kiekie-Resolution Analytical Characterization & Nā Koina Hoʻokuʻu

Pono ka holomua o ka unuhi ʻana i ka hōʻoia analytical ikaika e hōʻoia i ka ʻike kemika, ka maemae, a me ke kūʻokoʻa mai nā huahana ʻaoʻao immunogenic.

       ESI-HRMS MASS SPECTRUM (MOL Changes CoA Validation)
  100|                  [M+3H]3+ m/z = 1371.6842
     |                     |
   50|     [M+4H]4+        |         [M+2H]2+
     |   m/z = 1029.0151   |      m/z = 2057.0238
    0+-------------------------------------------------> m/z

Nā ʻenehana kālailai

  1. ʻO ke kiʻi kiʻekiʻe kiʻekiʻe ʻo Liquid Chromatography (UHPLC): Method optimized for resolving $D\text{-ʻO Glu}$, $D\text{-Ala}$, and $\beta\text{-ʻO Asp}$ hoʻonohonoho hou i nā isomers.
  2. Electrospray Ionization High-Resolution Mass Spectrometry (ESI-HRMS): Hoʻoholo nuipaʻa pololei i loko o $< 5\kikokikona{ ppm}$ kuhi hewa e hōʻoia i ke kaumaha molekala monoisotopic.
  3. ʻO ka hoʻonohonoho ʻana o Tandem MS/MS: Dissociation-Induced Dissociation (CID) a i ʻole Electron-Transfer Dissociation (ETD) e hōʻoia i nā kūlana hoʻopili lipid/PEG kikoʻī pūnaewele.

Palapala Hōʻoiaʻiʻo o ka ʻIkepili (KoA) Nā kikoʻī

Hōʻike ka papa ma lalo nei i nā koina hoʻokuʻu pae hoʻoponopono e pono ai no ka unuhi ʻana i nā peptide conjugates GLP-1:

ʻAno maikaʻi Ke Analytical Test Method Koina ʻae Kumu ʻepekema
ʻIke Kemika ESI-HRMS / MALDI-TOF MS Nā pāʻani i helu ʻia MW ($\pm 0.05\text{ A}$) E hōʻoia i ke kaʻina amino acid mua a me ka hoʻololi
Maemae Kemika RP-HPLC / UHPLC ($214\kikokikona{ nm} / 280\kikokikona{ nm}$) $\ge 98.0%$ (Wahi %) Hoʻemi i ka ʻoki ʻia a me ka oxidized peptide haumia
Hoʻokahi haumia RP-HPLC / LC-MS $\ka 0.5%$ Hoʻopaʻa paʻa i ka $n-1$ hoʻokahi a i ʻole nā ​​ʻano diastereomeric
Huina paumaele RP-HPLC $\ka 2.0%$ Hoʻokō i nā paepae hoʻoponopono ICH Q3A
Maʻemaʻe Stereoisomeric ʻO Chiral GC-MS / ʻO Marfey's Method $\le 0.2\text{ D-amino acid}%$ Kāohi i ka nalowale ʻana o ka hoʻoulu ʻana o ka mea hoʻokipa a me ka immunogenicity
TFA koena Ion Chromatography (IC) $\le 0.5%\text{ w/w}$ (a i ʻole e hoʻololi i ka Acetate/HCl) ʻO ka nui o ka TFA ke kumu o ka cytotoxicity i nā hoʻāʻo e pili ana i ke kelepona
Nā mea hoʻoheheʻe koena Kromatography kinoea (GC-HS) DMF $< 880\kikokikona{ ppm}$, NMP $< 530\kikokikona{ ppm}$ Hui i ka papa ICH Q3C 2 nā palena palekana solvent
Maʻiʻo Endotoxin LAL Kinetic Chromogenic ho'āʻo $< 0.01\kikokikona{ EU/mg}$ Critical for $in\text{ vivo}$ nā haʻawina holoholona preclinical
Hoʻopaʻa ʻia ʻo Microbial ʻO ka hoʻoheheʻe ʻia ʻana o ka Membrane Inoculation Holo (ʻAʻohe ulu i loko 14 lā) Hōʻoia ma o ka Papa 100 ka hoʻoponopono lumi maʻemaʻe

Ka hoʻopaʻa ʻana i kahi aniani, CoA hiki ke ʻike piha ʻia mai kahi hoa hāʻawi kiʻekiʻe-hoʻonā HPLC / MS CoA hiʻona hoʻopau i nā bottlenecks hōʻoia ma mua o ka hoʻouna ʻana i ka IND.


Ke kahua 5 — Nā koho hana e puka mai ana: Paʻi 3D Mākaukau GMP & Nā Pūnaehana Hoʻolaha Hou

ʻOiai nā mākua wai kuʻuna (nā ʻinikua ma lalo o ka ʻili) e hoʻomalu i nā lāʻau lapaʻau GLP-1 o kēia manawa, Ke hoʻohana nei nā polokalamu unuhi i nā paepae hana kiʻekiʻe Paʻi 3D Mākaukau GMP a Microfluidic Encapsulation—e wehe i na ala waha waha a me na hale hoopololei.

                  GMP-READY 3D PRINTING & FORMULATION PATHWAYS
                                       |
             +-------------------------+-------------------------+
             |                                                   |
             v                                                   v
   [Semi-Solid Extrusion (SSE)]                       [Subcutaneous Implants]
   - Multi-layer gastro-resistant oral tablets        - Biodegradable PLGA/PCL matrix
   - pH-responsive Eudragit L100-55 coatings          - Zero-order sustained release (1-3 months)
   - Protects peptide from stomach pepsin/acid       - Eliminates peak-to-trough plasma spikes

1. Semi-Solid Extrusion (SSE) 3D Pa'i no ka lawe waha

Hoʻopilikia nui ʻia ka hoʻokele waha o GLP-1 peptides e ka hōʻemi ʻana o ka waikawa gastric ($\kikokikona{pH } 1.5 – 2.0$) a me ka hoʻoheheʻe enzymatic e ka pepsin a me ka trypsin i loko o ka ʻōpū liʻiliʻi.

E like me ka mea i hōʻike ʻia ma Nature Research ma 3D-Printed Peptide Drug Delivery Systems, Semi-Solid Extrusion (SSE) 3Hiki i ka paʻi D ke hana ʻana i nā ʻano hoʻohālikelike paʻa waha me nā geometries core-shell paʻakikī:

  • Core: Lipidated GLP-1 analog i hui pū ʻia me nā mea hoʻonui permeation (e.g., Sodium Caprate / SNACK).
  • ʻO ka pūpū: 3ʻO ka pūnaewele polimer enteric paʻi D (Eudragit L100 / HPMC-AS) ʻaʻole hiki ke hoʻoheheʻe ʻia i ka pH gastric, e hoʻoheheʻe wikiwiki wale i ka hiki ʻana i ka duodenum ($\kikokikona{pH } > 6.0$).

$$\kikokikona{Ka helu hoʻoheheʻe } \hema(\frac{dM}{dt}\akau) = \frac{A \cdot D \cdot (C_s – C_b)}{h}$$

3D paʻi ʻana i nā ʻāpana (nozzle diameter $200-400\text{ }\mu\text{m}$, extrusion pressure $2.0-4.5\text{ pā}$, temperature $25^\circ\text{C} – 35^\circ\text{C}$) e ʻae i ka hoʻoponopono ʻana i ka geometry spatial me ka ʻole o ka hoʻohaʻahaʻa wela o ka peptide API conjugated.

2. Microfluidic Core-Shell Extrusion no nā Depot Subcutaneous

No ka pani ʻana i nā injection subcutaneous pinepine, Hoʻokumu nā ʻōnaehana paʻi microfluidic 3D mau i ka Poly bioerodible(lactic-co-glycolic acid) (PLGA) a i ʻole Polycaprolactone (PCL) micro-implants.

Ma ke kāohi ʻana i nā kinetics degradation polymer ($\kikokikona{KA:GA}$ ratio $50:50 \ʻākau ʻākau 75:25$), Hiki ke hana ʻia nā ʻaoʻao hoʻokuʻu no ka hōʻike ʻana i ka hoʻopuehu ʻole o ke kauoha 30 i 90 lā, ka mālama mau ʻana i ka therapeutic plasma concentration ($C_{ss}$) i loko o ka puka therapeutic ($C_{min} < C_{ss} < C_{max}$).


Mākaukau hoʻoponopono & Hoʻokō maikaʻi ʻo ICH

Ke hoʻololi nei nā polokalamu unuhi mai ka ʻike hope loa i ka Phase 1 Pono nā hoʻokolohua lapaʻau e hoʻohālikelike i nā kahe hana hana me ka International Council for Harmonization (I) alakai:

[ICH Q3A(R2)] : Control of Impurities in New Drug Substances (Threshold: > 0.05% ID, > 0.10% Qualification)
[ICH Q3B(R2)] : Control of Impurities in Finished Drug Products
[ICH Q3C(R8)] : Residual Solvent Control (DMF, NMP, DCM, Acetonitrile limits)
[ICH M7]     : Assessment and Control of DNA Reactive (Mutagenic) Impurities

Ke Kaʻina Hana Maʻemaʻe

No ka mea, post-synthesis terminal sterilization (ka autoclaving a i ʻole ka lāʻau gamma) ke hoʻohaʻahaʻa kemika o nā kaulahao ʻaoʻao lipid a me PEG, Pono ka hoʻokaʻawale peptide hope a me ka lyophilization i loko o kahi hōʻoia Papa 100 hale hoʻomaʻemaʻe ultra-sterile. Ka mālama ʻana i ka ISO 5 / Kāohi ʻia nā kūlana kahe o ka papa A laminar i ka pyrogen a me ka microbial contamination i ka wā o ka hoʻopiha piha ʻana i ka pauka.


Hiki ke unuhi & Hoʻokō Alanui

E alakaʻi i nā ʻepekema biopharma ma o ke koho ʻana i ke kaʻina hana mua e hoʻoponopono i ka scale-up, ʻO ka matrix hoʻoholo ma lalo e synthesizes kiʻi hoʻololi trade-offs:

Koho Hoololi Pōmaikaʻi mua ($in\text{ }vivo$) Hoʻonui ʻia ʻo Bottleneck Hoʻolālā hoʻohaʻahaʻa
Aib8 Pani Ke kū'ē kū'ē DPP-IV Haʻahaʻa ka hoʻohui ʻana ma muli o $N$-terminal steric hindrance E hoʻohana i ka HATU/HOAt a i ʻole ka hoʻohui pālua i ka wela kiʻekiʻe ($50^\circ\text{C}$)
C18 Diacid Lipidation Hoʻonui i ka hapalua ola ($>160\kikokikona{ h}$), Hoʻopaʻa HSA Ka hoʻoheheʻe ʻino, resin gelation, hoʻomaʻemaʻe HPLC paʻakikī Ma hope o ka hoʻoheheʻe ʻana i ka hoʻonā-phase bioconjugation; C4 RP-HPLC at $50^\circ\text{C}$
PEGylation (20-40 kDa) Hoʻomaʻemaʻe renal zero Polydispersity, hoʻonui viscosity, hoemi bioactivity Hoʻohui ʻia ʻo thiol-maleimide kikoʻī o ka pae; koho PEG monodisperse koʻikoʻi
3D Paʻi ʻia waha waha Hoʻokō hoʻomanawanui kiʻekiʻe ʻIke wela i ka wā extrusion, haʻahaʻa haʻahaʻa bioavailability waha Paʻi SSE haʻahaʻa wela; hui pū me nā mea hoʻonui permeation

Hoʻopili no ka holomua unuhi

Pono ka unuhi ʻana i nā moho incretin paʻakikī i kahi kaʻina hana i hoʻohui ʻia e hoʻopili i ka kemika, kālailai, a me ka hoʻokō hoʻoponopono. MOL Changes (https://molchanges.com/) hāʻawi i kahi kikoʻī R&D i hoʻolālā ʻia no ka hana hou biopharma:

  • Suite Hoʻololi Nui: Pau 300 hoʻololi pūʻulu hana, me nā diacid lipid maʻamau, Nā loulou PEG, nā ʻakika amino i hoʻopaʻa inoa ʻia, a me nā hōʻailona fluorescent.
  • Papa 100 Keena Hoʻomaʻemaʻe: ʻO nā kaiapuni hana sterile hou loa e hōʻoiaʻiʻo ana i ka endotoxin ultra-haʻahaʻa ($< 0.01\kikokikona{ EU/mg}$) a me ka sterility microbial.
  • Scalability ʻole: ʻO ka nānā ʻana i ka noiʻi Milligram i ka multigram/kilogram pilot synthesis me ka hōʻoiaʻiʻo ʻia ʻana o ka batch-to-batch reproducibility.
  • ʻO ka hōʻoia ʻana i ka maikaʻi o CoA: HPLC piha, ESI-HRMS, a me ka ʻano hoʻomaʻemaʻe chiral e hele pū ana me kēlā me kēia mea hoʻopuka.

Kāhea Hoʻonaʻauao ʻenehana: Ke ʻimi nei ʻoe i kahi GLP-1 a i ʻole incretin co-agonist sequence no ka unuhi preclinical? Hoʻokaʻaʻike i nā hoʻololi MOL no ke noi ʻana i kahi loiloi kūpono ʻo Bioconjugation a e loiloi i ka synthesis o kāu kaʻina, lipidation, a me ka hoʻonui ʻana i nā ʻāpana me kā mākou hui ʻenekinia kemika.


Nā kuhikuhi

  1. Knudsen, L. B., & Lau, J. (2019). ʻO ka ʻike a me ka hoʻomohala ʻana o Liraglutide a me Semaglutide. Nā palena i ka Endocrinology, 10, 155. DOI: 10.3389/slot.2019.00155 | PMID: 31024456 | Nānā Hoʻonui Half-Life
  2. ʻO Prada Brichtova, E., et al. (2024). Ka hopena o ka Lipidation ma ke ʻano, Oligomerization, a me ka hui ʻana o Glucagon-like Peptide 1. ACS Bioconjugate Chemistry, 35(4), 484-495. DOI: 10.1021/acs.bioconjchem.4c00012 | PMC: PMC10959496
  3. Kikowaena ʻIke Bachem. (2024). Koi GLP-1: He aha ka manaʻo no nā mea hana Peptide Industrial. Bachem Industrial Whitepaper
  4. Hui Laau Laau makua (PDA). (2025). Nā mea hou e hoʻohaunaele ana i ka ʻāina GLP-1: ʻO SPPS-a-LPPS Hybrid Synthesis. ʻatikala PDA Leta. PDA Publication Portal
  5. ʻO Zhang, Y., et al. (2025). Hoʻolālā i ka hoʻouna ʻana i ka GLP-1: Nā Kūlana Kūlana a me nā ʻano hana hoʻomohala paʻi 3D no ka hoʻomaʻamaʻa maikaʻi ʻia. Nature Scientific Reports, 10, 397. DOI: 10.1038/s41598-025-00397-4
  6. ʻAha Kūkākūkā o ka Honua no ka Harmonization (I). (2023). I Q3A(R2): Na Laau Laau Hou & I Q3C(R8): Hōʻuluʻulu Manaʻo Manaʻo no nā alakaʻi no nā mea hoʻoheheʻe koena. Keʻena Lapaʻau ʻEulopa (EMA) / Nā alakaʻi i hui pū ʻia e ka US FDA.
Miao He

Miao He

ʻepekema noiʻi ma nā ʻōnaehana hoʻouna Kaʻike kumu: Hāʻawi peptide waha, lipid nanoparticle (LNP) hoʻopili ʻana, nā peptides komo i loko o ke kelepona (CPPs), a me nā hoʻopuka hoʻokuʻu mau.

Pilikino: ʻO nā luʻi nui i ka hoʻomohala ʻana i nā lāʻau peptide aia i loko o ko lākou mau hapalua ola pōkole a paʻakikī me ka hoʻokele waha, a ʻo Miao ʻO ia kekahi loea alakaʻi i ka hoʻoponopono ʻana i kēia mau pilikia. Loaʻa iā ia ka ʻike nui ma ke kahua o nā ʻōnaehana lawe peptide. Ke hoʻomau nei ʻo ia i ka hoʻomohala ʻana i nā mea hoʻonui permeation novel a me nā nanospheres e hoʻomaikaʻi nui i ka bioavailability o peptides..

ʻIke ʻia & Nā alakaʻi hoʻoponopono
Nānā ʻia e: Ka poe akamai kumuhana
Kaʻana like i kēia ʻatikala
Home Huli Whatsapp Nā lawelawe Huahana